Literature DB >> 16024535

Is expectant management of sonographically benign adnexal cysts an option in selected asymptomatic premenopausal women?

Juan Luis Alcázar1, Gerardo Castillo, Matías Jurado, Guillermo López García.   

Abstract

BACKGROUND: The objective was to assess whether expectant management of sonographically benign ovarian cysts may be an option for selected asymptomatic premenopausal women.
METHODS: This is a prospective observational longitudinal study. Between January 1997 and December 2002, 323 asymptomatic premenopausal women (mean age: 40.6 years; range: 19-50 years) diagnosed as having a sonographically benign ovarian cyst measuring <6 cm were offered conservative management with periodic follow-up at 6-12 month intervals. In all cases, a first check was performed 3 months after diagnosis to confirm the 'persistent' nature of the cyst. A total of 120 women agreed to participate in this study and constitute the basis of the data presented.
RESULTS: Mean diameter at diagnosis for the most frequent lesions were as follows: endometrioma 3.3 cm (SD 1.5); simple cyst 4.1 cm (SD 1.6); dermoid cyst 3.2 cm (SD 1.4); haemorrhagic cyst 3.5 cm (SD 1.2); hydrosalpinx 2.9 cm (SD 1.0). With a median follow-up of 42 months (range: 18-94 months), most lesions remained unchanged, both in size and sonographic appearance. Ten cysts (8.3%) disappeared during follow-up, all of them after more than 2 years of follow-up. No patient has developed signs or symptoms suggesting ovarian cancer.
CONCLUSION: Most sonographically benign ovarian cysts remain unchanged during long-term follow-up. Our data would support conservative management in these cases.

Entities:  

Mesh:

Year:  2005        PMID: 16024535     DOI: 10.1093/humrep/dei206

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

Review 1.  Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement.

Authors:  Deborah Levine; Douglas L Brown; Rochelle F Andreotti; Beryl Benacerraf; Carol B Benson; Wendy R Brewster; Beverly Coleman; Paul Depriest; Peter M Doubilet; Steven R Goldstein; Ulrike M Hamper; Jonathan L Hecht; Mindy Horrow; Hye-Chun Hur; Mary Marnach; Maitray D Patel; Lawrence D Platt; Elizabeth Puscheck; Rebecca Smith-Bindman
Journal:  Radiology       Date:  2010-05-26       Impact factor: 11.105

2.  Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass.

Authors:  Elizabeth Lokich; Marguerite Palisoul; Nicole Romano; M Craig Miller; Katina Robison; Ashley Stuckey; Paul DiSilvestro; Cara Mathews; C O Granai; Geralyn Lambert-Messerlian; Richard G Moore
Journal:  Gynecol Oncol       Date:  2015-09-11       Impact factor: 5.482

Review 3.  Ovarian Mature Cystic Teratoma: Challenges of Surgical Management.

Authors:  Abha Sinha; Ayman A A Ewies
Journal:  Obstet Gynecol Int       Date:  2016-03-24

4.  Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen.

Authors:  Veronika Seebacher; Stefanie Aust; David D'Andrea; Christoph Grimm; Elisabeth Reiser; Denise Tiringer; Hannah Von Mersi; Stephan Polterauer; Alexander Reinthaller; Samir Helmy-Bader
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

5.  The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.

Authors:  Kyung Hee Han; Noh Hyun Park; Jin Ju Kim; Sunmie Kim; Hee Seung Kim; Maria Lee; Yong Sang Song
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

6.  Fertility in multiple recurrent bilateral ovarian teratomas: A case report.

Authors:  Maroun Bou Zerdan; Youssef Bouferraa; Raffi Boyrazian; Rana Skaf
Journal:  SAGE Open Med Case Rep       Date:  2022-01-30

7.  A Nomogram Combined Radiomic and Semantic Features as Imaging Biomarker for Classification of Ovarian Cystadenomas.

Authors:  Shushu Pan; Zhongxiang Ding; Lexing Zhang; Mei Ruan; Yanna Shan; Meixiang Deng; Peipei Pang; Qijun Shen
Journal:  Front Oncol       Date:  2020-06-01       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.